SCHEMBL8793986

SCHEMBL8793986

Bc1cccc(F)c1NC(=O)Nc1cc(C(F)(F)F)ccc1OC

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 8/20 0.51
MAPK14 Q16539 1/20 0.48
KDM4E B2RXH2 3/20 0.47
HPGD P15428 1/20 0.47
POLB P06746 1/20 0.46
BRAF P15056 1/20 0.46
MAPT P10636 4/20 0.45
LMNA P02545 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HTT P42858 2/20 0.44
RXFP1 Q9HBX9 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30863330 0.87 RAF1 (0.51) RAF1MAPK14KDM4EHPGDPOLB
SCHEMBL31686438 0.87 RAF1 (0.51) RAF1MAPK14KDM4EHPGDPOLB
SCHEMBL379112 0.87 RAF1 (0.51) RAF1MAPK14KDM4EHPGDPOLB
SCHEMBL30863324 0.87 RAF1 (0.51) RAF1MAPK14KDM4EHPGDPOLB
SCHEMBL30667490 0.83 RAB9A (0.59) RAF1MAPK14KDM4EHPGDBRAF
SCHEMBL379862 0.83 RAB9A (0.59) RAF1MAPK14KDM4EHPGDBRAF
SCHEMBL31440788 0.83 KMT2A (0.61) RAF1MAPK14KDM4EHPGDPOLB
SCHEMBL379165 0.81 RAF1 (0.47) RAF1MAPK14KDM4EHPGDPOLB
SCHEMBL4534203 0.81 RAF1 (0.47) RAF1MAPK14KDM4EHPGDPOLB
SCHEMBL15229756 0.81 RAF1 (0.47) RAF1MAPK14KDM4EHPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120130072-A1 PROCESS FOR THE PREPARATION OF DIHYDROQUINAZOLINES AICURIS GMBH & CO. KG (DE) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120130072-A1 PROCESS FOR THE PREPARATION OF DIHYDROQUINAZOLINES QDPR, DHPS, DHX15 RAF1 2551/4885MAPK14 1667/4885KDM4E 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.